Neuroblastoma signalling models unveil combination therapies targeting feedback-mediated resistance.
Very high risk neuroblastoma is characterised by increased MAPK signalling, and targeting MAPK signalling is a promising therapeutic strategy. We used a deeply characterised panel of neuroblastoma cell lines and found that the sensitivity to MEK inhibitors varied drastically between these cell lines...
Guardado en:
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/6c6e8d855b1e45b79a37ebbd2f6a6b10 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
id |
oai:doaj.org-article:6c6e8d855b1e45b79a37ebbd2f6a6b10 |
---|---|
record_format |
dspace |
spelling |
oai:doaj.org-article:6c6e8d855b1e45b79a37ebbd2f6a6b102021-12-02T19:57:59ZNeuroblastoma signalling models unveil combination therapies targeting feedback-mediated resistance.1553-734X1553-735810.1371/journal.pcbi.1009515https://doaj.org/article/6c6e8d855b1e45b79a37ebbd2f6a6b102021-11-01T00:00:00Zhttps://doi.org/10.1371/journal.pcbi.1009515https://doaj.org/toc/1553-734Xhttps://doaj.org/toc/1553-7358Very high risk neuroblastoma is characterised by increased MAPK signalling, and targeting MAPK signalling is a promising therapeutic strategy. We used a deeply characterised panel of neuroblastoma cell lines and found that the sensitivity to MEK inhibitors varied drastically between these cell lines. By generating quantitative perturbation data and mathematical modelling, we determined potential resistance mechanisms. We found that negative feedbacks within MAPK signalling and via the IGF receptor mediate re-activation of MAPK signalling upon treatment in resistant cell lines. By using cell-line specific models, we predict that combinations of MEK inhibitors with RAF or IGFR inhibitors can overcome resistance, and tested these predictions experimentally. In addition, phospho-proteomic profiling confirmed the cell-specific feedback effects and synergy of MEK and IGFR targeted treatment. Our study shows that a quantitative understanding of signalling and feedback mechanisms facilitated by models can help to develop and optimise therapeutic strategies. Our findings should be considered for the planning of future clinical trials introducing MEKi in the treatment of neuroblastoma.Mathurin DorelBertram KlingerTommaso MariJoern ToedlingEric BlancClemens MesserschmidtMichal Nadler-HollyMatthias ZiehmAnja SieberFalk HertwigDieter BeuleAngelika EggertJohannes H SchulteMatthias SelbachNils BlüthgenPublic Library of Science (PLoS)articleBiology (General)QH301-705.5ENPLoS Computational Biology, Vol 17, Iss 11, p e1009515 (2021) |
institution |
DOAJ |
collection |
DOAJ |
language |
EN |
topic |
Biology (General) QH301-705.5 |
spellingShingle |
Biology (General) QH301-705.5 Mathurin Dorel Bertram Klinger Tommaso Mari Joern Toedling Eric Blanc Clemens Messerschmidt Michal Nadler-Holly Matthias Ziehm Anja Sieber Falk Hertwig Dieter Beule Angelika Eggert Johannes H Schulte Matthias Selbach Nils Blüthgen Neuroblastoma signalling models unveil combination therapies targeting feedback-mediated resistance. |
description |
Very high risk neuroblastoma is characterised by increased MAPK signalling, and targeting MAPK signalling is a promising therapeutic strategy. We used a deeply characterised panel of neuroblastoma cell lines and found that the sensitivity to MEK inhibitors varied drastically between these cell lines. By generating quantitative perturbation data and mathematical modelling, we determined potential resistance mechanisms. We found that negative feedbacks within MAPK signalling and via the IGF receptor mediate re-activation of MAPK signalling upon treatment in resistant cell lines. By using cell-line specific models, we predict that combinations of MEK inhibitors with RAF or IGFR inhibitors can overcome resistance, and tested these predictions experimentally. In addition, phospho-proteomic profiling confirmed the cell-specific feedback effects and synergy of MEK and IGFR targeted treatment. Our study shows that a quantitative understanding of signalling and feedback mechanisms facilitated by models can help to develop and optimise therapeutic strategies. Our findings should be considered for the planning of future clinical trials introducing MEKi in the treatment of neuroblastoma. |
format |
article |
author |
Mathurin Dorel Bertram Klinger Tommaso Mari Joern Toedling Eric Blanc Clemens Messerschmidt Michal Nadler-Holly Matthias Ziehm Anja Sieber Falk Hertwig Dieter Beule Angelika Eggert Johannes H Schulte Matthias Selbach Nils Blüthgen |
author_facet |
Mathurin Dorel Bertram Klinger Tommaso Mari Joern Toedling Eric Blanc Clemens Messerschmidt Michal Nadler-Holly Matthias Ziehm Anja Sieber Falk Hertwig Dieter Beule Angelika Eggert Johannes H Schulte Matthias Selbach Nils Blüthgen |
author_sort |
Mathurin Dorel |
title |
Neuroblastoma signalling models unveil combination therapies targeting feedback-mediated resistance. |
title_short |
Neuroblastoma signalling models unveil combination therapies targeting feedback-mediated resistance. |
title_full |
Neuroblastoma signalling models unveil combination therapies targeting feedback-mediated resistance. |
title_fullStr |
Neuroblastoma signalling models unveil combination therapies targeting feedback-mediated resistance. |
title_full_unstemmed |
Neuroblastoma signalling models unveil combination therapies targeting feedback-mediated resistance. |
title_sort |
neuroblastoma signalling models unveil combination therapies targeting feedback-mediated resistance. |
publisher |
Public Library of Science (PLoS) |
publishDate |
2021 |
url |
https://doaj.org/article/6c6e8d855b1e45b79a37ebbd2f6a6b10 |
work_keys_str_mv |
AT mathurindorel neuroblastomasignallingmodelsunveilcombinationtherapiestargetingfeedbackmediatedresistance AT bertramklinger neuroblastomasignallingmodelsunveilcombinationtherapiestargetingfeedbackmediatedresistance AT tommasomari neuroblastomasignallingmodelsunveilcombinationtherapiestargetingfeedbackmediatedresistance AT joerntoedling neuroblastomasignallingmodelsunveilcombinationtherapiestargetingfeedbackmediatedresistance AT ericblanc neuroblastomasignallingmodelsunveilcombinationtherapiestargetingfeedbackmediatedresistance AT clemensmesserschmidt neuroblastomasignallingmodelsunveilcombinationtherapiestargetingfeedbackmediatedresistance AT michalnadlerholly neuroblastomasignallingmodelsunveilcombinationtherapiestargetingfeedbackmediatedresistance AT matthiasziehm neuroblastomasignallingmodelsunveilcombinationtherapiestargetingfeedbackmediatedresistance AT anjasieber neuroblastomasignallingmodelsunveilcombinationtherapiestargetingfeedbackmediatedresistance AT falkhertwig neuroblastomasignallingmodelsunveilcombinationtherapiestargetingfeedbackmediatedresistance AT dieterbeule neuroblastomasignallingmodelsunveilcombinationtherapiestargetingfeedbackmediatedresistance AT angelikaeggert neuroblastomasignallingmodelsunveilcombinationtherapiestargetingfeedbackmediatedresistance AT johanneshschulte neuroblastomasignallingmodelsunveilcombinationtherapiestargetingfeedbackmediatedresistance AT matthiasselbach neuroblastomasignallingmodelsunveilcombinationtherapiestargetingfeedbackmediatedresistance AT nilsbluthgen neuroblastomasignallingmodelsunveilcombinationtherapiestargetingfeedbackmediatedresistance |
_version_ |
1718375781764169728 |